PLGA-PEG reactive intermediates from PolySciTech used in development of targeted nanoparticles for treatment of heart-disease

 

Although nanoparticles are often applied for cancer targeting there is nothing preventing this platform technique from being applied to other diseases. For example, nanoparticles can be applied to treating heart-disease. Recently, researchers at University of Texas at Arlington used PLGA (AP154) and PLGA-NHS (AI097) and PLGA-PEG-NHS (AI064), and PLGA-PEG-COOH (AI166) from PolySciTech (www.polyscitech.com) to create a series of nanoparticles designed to repair damage to arterial walls and prevent further heart disease. This research holds promise to improve cardiovascular care. Read more: Khang, Min Kyung, Aneetta Elizabeth Kuriakose, Tam Nguyen, Cynthia My-Dung Co, Jun Zhou, Thuy Thi Dang Truong, Kytai Truong Nguyen, and Liping Tang. "Enhanced Endothelial Cell Delivery for Repairing Injured Endothelium via Pretargeting Approach and Bioorthogonal Chemistry." ACS Biomaterials Science & Engineering (2020). https://pubs.acs.org/doi/abs/10.1021/acsbiomaterials.0c00957

“Arterial wall injury often leads to endothelium cell activation, endothelial detachment, and atherosclerosis plaque formation. While abundant research efforts have been placed on treating the end stages of the disease, no cure has been developed to repair injured and denude endothelium often occurred at an early stage of atherosclerosis. Here, a pretargeting cell delivery strategy using combined injured endothelial targeting nanoparticles and bioorthogonal click chemistry approach was developed to deliver endothelial cells to replenish the injured endothelium via a two-step process. First, nanoparticles bearing glycoprotein 1b α (Gp1bα) proteins and tetrazine (Tz) were fabricated to provide a homogeneous nanoparticle coating on an injured arterial wall via the interactions between Gp1bα and von Willebrand factor (vWF), a ligand that is present on denuded endothelium. Second, transplanted endothelium cells bearing transcyclooctene (TCO) would be quickly immobilized on the surfaces of nanoparticles via TCO:Tz reactions. In vitro binding studies under both static and flow conditions confirmed that our novel Tz-labeled Gp1bα-conjugated poly(lactic-co-glycolic acid) (PLGA) nanoparticles can successfully pretargeted toward the injured site and support rapid adhesion of endothelial cells from the circulation. Ex vivo results also confirm that such an approach is highly efficient in mediating the local delivery of endothelial cells at the sites of arterial injury. The results support that this pretargeting cell delivery approach may be used for repairing injured endothelium in situ at its early stage.”